newsfilter
← Latest News
GlobeNewswire·

Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update

- Groundbreaking interim results from U.S. REGAIN trial in recurrent glioblastoma demonstrate 100% local disease control, 67% complete response rate, and favorable safety profile - - Completion of patient enrollment